Skip to content
2000
Volume 21, Issue 4
  • ISSN: 1573-3963
  • E-ISSN: 1875-6336

Abstract

Background

An off-label medication involves the use of an approved drug for an unapproved indication, population, route of administration, or dosage.The physiological state of children differs from that of adults, making the adult formulation potentially dangerous to children. Off-label prescribing is quite common in children due to challenges in the development of pediatric formulations. The current study was conducted to determine the awareness, practice, and views of pediatricians, general physicians, and pharmacists about prescribing Off-label medication to pediatric patients in Eastern Province, Saudi Arabia.

Methods

A cross-sectional study based on a questionnaire was conducted among pediatricians, general physicians, and pharmacists (clinical and community) in Eastern Province, Saudi Arabia. Statistical analysis was conducted using the data exported from Google Forms (Mountain View, California, USA) and Microsoft Excel (Version 2016) and then exported into Statistical Package for Social Sciences (SPSS) version 26.0 (IBM, Inc., Armonk, NY, USA). Chi-square was deemed suitable. The level of significance was set at 0.05.

Results

Among the study participants, 53(35.09%) were pharmacists, followed by 24(15.89%) others, 22(14.565) pediatricians, 19(12.58%) other specialists, 17(11.25%) general physicians, and 16(10.59%) were clinical pharmacist. About 73(48.34%) described the definition of off-label correctly. About 114(75.49%) believed that parents and guardians must be informed about off-label medicine prescribed to their children. About 52(34.43%) had concerns about the safety of the medication, and 98(64.90%) believed they should be tested in pediatrics during clinical trials. Further, 97(64.23%) considered themselves not enough knowledgeable about off-label medications. The barriers reported by the participants were as follows: 89(58.945%) said lack of information resources, 71(47.01%) said lack of training, 56(37.08%) said lack of information on the safety of excipients used in pediatrics, 47(31.12%) said lack of formulary, 44(29.13%) said lack of guidelines, and 58(5.29%) said lack of information related to the safety of excipient concentration in pediatrics. The proportion of healthcare professionals who agreed that excipients in adult medication may be harmful to pediatrics was 103(68.21%). The drugs most often prescribed as off-label were paracetamol 54(21.68%), followed by Phenobarbital 35(14%), and Amoxicillin 33(13.25%).

Conclusion

There are a considerable number of healthcare professionals unaware of the description of off-label medication. The majority have concerns over the safety and efficacy of the off-label drugs and believe that most frequently used off-label drugs in pediatrics must be tested in pediatrics during clinical trials. In addition, excipient safety data are of considerable importance to ensure off-label drug safety in pediatrics, who believe their knowledge is inadequate and need proper guidelines and training on this issue.

Loading

Article metrics loading...

/content/journals/cpr/10.2174/0115733963298903240614072717
2024-06-26
2025-09-08
Loading full text...

Full text loading...

References

  1. NevilleK.A. FrattarelliD.A.C. GalinkinJ.L. GreenT.P. JohnsonT.D. PaulI.M. Van Den AnkerJ.N. American academy of pediatrics committee on drugs. Off-label use of drugs in children..Pediatrics2014133356356710.1542/peds.2013‑406024567009
    [Google Scholar]
  2. Understanding unapproved use of approved drugs "Off Label".2023Available from: https://www.fda.gov/patients/learn-about- expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label#:~:text=Unapproved%20use%20of%20an%20approved,a%20different%20type%20of%20cancer.
  3. MasonJ. PirmohamedM. NunnT. Off-label and unlicensed medicine use and adverse drug reactions in children: A narrative review of the literature.Eur. J. Clin. Pharmacol.2012681212810.1007/s00228‑011‑1097‑121779968
    [Google Scholar]
  4. GideyM.T. GebretsadkanY.G. TsadikA.G. WelieA.G. AssefaB.T. Off-label and unlicensed drug use in Ayder comprehensive specialized hospital neonatal intensive care unit.Ital. J. Pediatr.20204614110.1186/s13052‑020‑0809‑532245504
    [Google Scholar]
  5. Evidence of harm from off-label or unlicensed medicines in children.2004Available from: https://www.ema.europa.eu/system/files/documents/other/wc500004021_en.pdf
  6. SutcliffeA.G. Prescribing medicines for children.BMJ19993197202707110.1136/bmj.319.7202.7010398609
    [Google Scholar]
  7. GiurinM.S. TrojniakM.P. ArboA. CarrozziM. AbbracciaventoG. MonastaL. ZanusC. Safety of off-label pharmacological treatment in pediatric neuropsychiatric disorders: A global perspective from an observational study at an italian third level children’s hospital.Front. Pharmacol.202213483769210.3389/fphar.2022.83769235496268
    [Google Scholar]
  8. AbuAlsaudZ. AlshaybanD. JosephR. PottooF.H. LuccaJ.M. Off-label medications use in the eastern province of Saudi Arabia: The views of general practitioners, pediatricians, and other specialists.Hosp. Pharm.2020551374310.1177/001857871881786131983765
    [Google Scholar]
  9. BelaynehA. TadeseE. MollaF. Safety and biopharmaceutical challenges of excipients in off-label pediatric formulations.Int. J. Gen. Med.20201391051106610.2147/IJGM.S28033033204140
    [Google Scholar]
  10. IvanovskaV. RademakerC.M.A. van DijkL. Mantel-TeeuwisseA.K. Pediatric drug formulations: A review of challenges and progress.Pediatrics2014134236137210.1542/peds.2013‑322525022739
    [Google Scholar]
  11. DresserR. FraderJ. Off-label prescribing: A call for heightened professional and government oversight.J. Law Med. Ethics2009373476486, 39610.1111/j.1748‑720X.2009.00408.x19723258
    [Google Scholar]
  12. TeferaY.G. GebresillassieB.M. MekuriaA.B. AbebeT.B. ErkuD.A. SeidN. BeshirH.B. Off-label drug use in hospitalized children: A prospective observational study at Gondar University Referral Hospital, Northwestern Ethiopia.Pharmacol. Res. Perspect.201752e0030410.1002/prp2.30428357130
    [Google Scholar]
  13. AlyamiD. AlyamiA.A. AlhossanA. SalahM. Awareness and views of pharmacists and physicians toward prescribing of drugs for off-label use in the pediatric population in Saudi Arabia.Cureus2022143e2308210.7759/cureus.2308235464499
    [Google Scholar]
  14. HillP. Off licence and off label prescribing in children: Litigation fears for physicians.Arch Dis Child200590Suppl 1i17i1810.1136/adc.2004.058867
    [Google Scholar]
  15. AliM.D. HatefE.A.J. A review article: Types of sampling and sample size determination in health and social science research.J. Young Pharm.2024162204215
    [Google Scholar]
  16. AliM.D. AlmadanL.Z. AlghamdiR.A. AlghamdiA.S. AlmarhoonS.A. HassanY.A.M. AhmadA. GhosnS.A. BanuN. EltrafiZ. Evaluation of prevalence of side-effects associated with booster dose of mrna-based covid-19 vaccine among healthcare workers in eastern province, Saudi Arabia: A descriptive cross-sectional study.Infect. Drug Resist.20221594335434610.2147/IDR.S37426535971558
    [Google Scholar]
  17. MeiM. XuH. WangL. HuangG. GuiY. ZhangX. Current practice and awareness of pediatric off-label drug use in Shanghai, China -a questionnaire-based study.BMC Pediatr.201919128110.1186/s12887‑019‑1664‑731409339
    [Google Scholar]
  18. AllenH.C. GarbeM.C. LeesJ. AzizN. ChaabanH. MillerJ.L. JohnsonP. DeLeonS. Off-label medication use in children, more common than we think: A systematic review of the literature.J. Okla. State Med. Assoc.2018111877678331379392
    [Google Scholar]
  19. NevilleK.A. FrattarelliD.A.C. GalinkinJ.L. GreenT.P. JohnsonT.D. PaulI.M. Van Den AnkerJ.N. American Academy of Pediatrics Committee on Drugs Off-label use of drugs in children.Pediatrics2014133356356710.1542/peds.2013‑406024567009
    [Google Scholar]
  20. CBAHI Standards.2024Available from: https://portal.cbahi.gov.sa/english/cbahi-standards
  21. SharmaA.N. ArangoC. CoghillD. GringrasP. NuttD.J. PrattP. YoungA.H. HollisC. BAP position statement: Off-label prescribing of psychotropic medication to children and adolescents.J. Psychopharmacol.201630541642110.1177/026988111663610727098018
    [Google Scholar]
  22. BakouniH. BerbicheD. VasiliadisH.M. Off-label use of antipsychotics and associated factors in community living older adults.Aging Ment. Health201923215816510.1080/13607863.2017.140158329156947
    [Google Scholar]
  23. PolakaS. GomteS.S. PandeyV. TellaJ.D. TekadeM. SharmaM.C. MoluguluN. TekadeR.K. Chapter 19 - Pharmaceutical excipients: Special focus on adverse interactions.Advances in Pharmaceutical Product Development and Research, Pharmacokinetics and Toxicokinetic ConsiderationsAcademic Press20222
    [Google Scholar]
  24. SchrierL. HadjipanayisA. StirisT. Ross-RussellR.I. ValiulisA. TurnerM.A. ZhaoW. De CockP. de WildtS.N. AllegaertK. van den AnkerJ. Off-label use of medicines in neonates, infants, children, and adolescents: A joint policy statement by the european academy of pediatrics and the european society for developmental perinatal and pediatric pharmacology.Eur. J. Pediatr.2020179583984710.1007/s00431‑019‑03556‑931897842
    [Google Scholar]
  25. Guideline on good pharmacovigilance practices (GVP).2011Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf
/content/journals/cpr/10.2174/0115733963298903240614072717
Loading
/content/journals/cpr/10.2174/0115733963298903240614072717
Loading

Data & Media loading...


  • Article Type:
    Research Article
Keyword(s): awareness; FDA; health professionals; knowledge; Off-label; pediatrics; Saudi Arabia
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test